Stevanato Group STVN · NYSE
$19.44 -1.04% (-$0.21)
Summary
54 / 100 · Bulios Score
What speaks for it
- Out of every 100 EUR of revenue, 11 EUR is left as net profit.
- Analysts expect revenue to grow by 12% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share fell by 2.6% a year over the last 3 years.
- It reports a profit, yet spends more cash than it brings in.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 35.9 EUR for 1 EUR of yearly profit. Over the last five years it was 39.7 EUR on average.
Valuation in detailIs it growing?
SlowlyRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 11% a year over 5 years. Over the last 3 years it grew by 5.0% a year. For the next fiscal year analysts expect revenue to grow by 12%. Earnings per share fell by 2.6% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 EUR of revenue goes
- Cost of sales 71 EUR
- Research and development 2.1 EUR
- Sales and administration 11 EUR
- Taxes and other 5.1 EUR
- Net profit 11 EUR
Net profit, industry median (Medical - Instruments & Supplies) 8.4 EUR
Out of every 100 EUR of revenue, 11 EUR is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash. The debt score is high even though free cash flow is negative.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 0.32%
- Paid out of profit
- 11%
- Raised in a row
- 3 years
You receive $0.06 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 5
- Hold 3
- Sell 0
Today's price within the analysts' price targets
The average target of $25.58 is 32% above today's price. 63% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
The company reports no revenue by product.
By region
- Europe Middle East And Africa 54%
- North America 28%
- Asia Pacific 7.9%
- ITALY 7.3%
- South America 2.5%
Europe Middle East And Africa brings in 54% of revenue. North America grew fastest, by 13% a year.
Segments in detail